BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20013086)

  • 1. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.
    Balermpas P; Hambek M; Seitz O; Rödel C; Weiss C
    Strahlenther Onkol; 2009 Dec; 185(12):775-81. PubMed ID: 20013086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
    Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution.
    Milanović D; Jeremić B; Grosu AL; Rücker G; Henke M
    Strahlenther Onkol; 2013 Oct; 189(10):842-8. PubMed ID: 23861154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
    Zwicker F; Roeder F; Thieke C; Timke C; Münter MW; Huber PE; Debus J
    Strahlenther Onkol; 2011 Jan; 187(1):32-8. PubMed ID: 21234529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
    Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
    Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.
    Vargo JA; Ferris RL; Ohr J; Clump DA; Davis KS; Duvvuri U; Kim S; Johnson JT; Bauman JE; Gibson MK; Branstetter BF; Heron DE
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):480-8. PubMed ID: 25680594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
    Kovács AF; Schiemann M; Turowski B
    J Craniomaxillofac Surg; 2002 Apr; 30(2):112-20. PubMed ID: 12069515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
    Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
    Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade.
    Milanovic D; Jeremic B; Kayser G; Rischke HC; Pfeiffer J; Henke A
    Strahlenther Onkol; 2012 Jun; 188(6):518-22. PubMed ID: 22526230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
    Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
    Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
    Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume.
    Chao KS; Ozyigit G; Blanco AI; Thorstad WL; Deasy JO; Haughey BH; Spector GJ; Sessions DG
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):43-50. PubMed ID: 15093897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.
    Dornoff N; Weiß C; Rödel F; Wagenblast J; Ghanaati S; Atefeh N; Rödel C; Balermpas P
    Strahlenther Onkol; 2015 Aug; 191(8):656-64. PubMed ID: 26004121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
    Dirix P; Nuyts S
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure.
    Daly ME; Le QT; Maxim PG; Loo BW; Kaplan MJ; Fischbein NJ; Pinto H; Chang DT
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1339-46. PubMed ID: 19540068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
    Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
    Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
    Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
    Hehr T; Classen J; Belka C; Welz S; Schäfer J; Koitschev A; Bamberg M; Budach W
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1423-31. PubMed ID: 15817346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.